Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric Models
Therapeutic Innovation & Regulatory Science · 2026-07 · 60 (4) · 1084-1093
DOI: 10.1007/s43441-026-00960-w ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 28.03.2026. Verfasst von Gloria Nnadwa Alhassan. Beteiligte Einrichtung: Department of Nursing, Faculty of Health Sciences, Istanbul Gelişim University, Istanbul, Turkey. gnalhassan@gelisim.edu.tr. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Aniline Compounds, Acrylamides, Lung Neoplasms. Die Arbeit nennt 56 Literaturangaben.
Abstract (Originalsprache)
Health technology assessments (HTAs) for targeted therapies like osimertinib require models capturing individual pharmacokinetic/pharmacodynamic (PK/PD) variability in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Traditional models often fail to reflect these dynamics adequately. This study compared a pharmacometric-based model (PMX) with four traditional frameworks to evaluate osimertinib's cost-utility from a healthcare payer perspective. A virtual cohort of 1,000 patients with advanced EGFR-mutant NSCLC received osimertinib (80 mg daily) or comparator first-line EGFR-tyrosine kinase inhibitors (gefitinib/erlotinib). Models projected survival, adverse events (AEs), quality-adjusted life years (QALYs), and costs over 2 years. ICURs used PMX as benchmark. The PMX model yielded highest QALYs (1.48) and lowest ICUR ($82,000/QALY vs. comparator), outperforming traditional models (ICUR deviations - 21% to + 40%). TTE exponential showed most divergence due to constant hazard. Probabilistic analyses confirmed PMX superiority across willingness-to-pay thresholds. Pharmacometric models, enabling individualized dosing and exposure-driven effects, provide more biologically plausible estimates, supporting their integration into HTAs for precision oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nursing, Faculty of Health Sciences, Istanbul Gelişim University, Istanbul, Turkey. gnalhassan@gelisim.edu.tr.
Zitieren
APA
Alhassan, G. N. (2026). Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric Models. Therapeutic Innovation & Regulatory Science, 60(4), 1084-1093. https://doi.org/10.1007/s43441-026-00960-w
Vancouver
Alhassan GN. Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric Models. Therapeutic Innovation & Regulatory Science. 2026;60(4):1084-1093. doi:10.1007/s43441-026-00960-w
BibTeX
@article{Alhassan2026,
author = {Alhassan, Gloria Nnadwa},
title = {Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric Models},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2026},
volume = {60},
number = {4},
pages = {1084--1093},
doi = {10.1007/s43441-026-00960-w}
}
EUVIMED